Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)
August 14, 2024 6:12 AM EDTBTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).
The analyst comments "Enrolling a trial with a placebo arm when an active commercial drug is available is historically challenging, so we see Acumen's comments about the rapid enrollment of the P2 trial for Sabirnetug as very encouraging. Talking with management, both the therapeutic premise of a safer antibody that may also be more... More
